Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22744059 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL30321098 | 1.00 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL9547890 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL9331327 | 0.79 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL5581899 | 0.79 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL27828227 | 0.76 | SLC6A3 (0.42) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL21742321 | 0.75 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL19301718 | 0.75 | CYP1A2 (0.46) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL21742133 | 0.75 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 | |
| SCHEMBL28966787 | 0.75 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235957-A1 | P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| EP-3891149-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891148-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-11067580-B2 | Compounds and methods for conjugation of biomolecules | Life Technologies Corporation (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200333351-A1 | Compounds and Methods for Conjugation of Biomolecules | Life Technologies Corporation | 2020-10-22 | — | — | US | disclosed |
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| EP-1149092-B1 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| CN-1331689-A | 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | disclosed |
| US-6313310-B1 | JUN N-TERMINAL KINASE (JNK) ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC ARTHRITIS AND NEURO-DEGENERATIVE DISEASE TREATMENT | HOFFMANN-LA ROCHE INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1149092-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000035906-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0888355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034899-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | SLC6A2 984/4885SLC6A4 2907/4885SLC6A3 1724/4885 |
| US-20200333351-A1 | Compounds and Methods for Conjugation of Biomolecules | LIG3, LIG1, HLCS | SLC6A2 4525/4885SLC6A4 4646/4885SLC6A3 2993/4885 |
| US-11067580-B2 | Compounds and methods for conjugation of biomolecules | LIG3, LIG1, HLCS | SLC6A2 4525/4885SLC6A4 4646/4885SLC6A3 2993/4885 |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | SLC6A2 1118/4885SLC6A4 1645/4885SLC6A3 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.